Updated guidelines for chronic active Epstein-Barr virus disease.
Kawada JI, Ito Y, Ohshima K, Yamada M, Kataoka S, Muramatsu H, Sawada A, Wada T, Imadome KI, Arai A, Iwatsuki K, Ohga S, Kimura H; Committee for Guidelines for the Management of Chronic Active EBV Disease, Related Disorders (the MHLW Research Team in Japan).
Int J Hematol. 2023 Nov;118(5):568-576. doi: 10.1007/s12185-023-03660-5. Epub 2023 Sep 20.
Epstein-Barr virus (EBV) reactivation and therapeutic inhibitors.
Kerr JR.
J Clin Pathol. 2019 Oct;72(10):651-658. doi: 10.1136/jclinpath-2019-205822. Epub 2019 Jul 17.
Infectious Mononucleosis: An Updated Review.
Leung AKC, Lam JM, Barankin B.
Curr Pediatr Rev. 2024;20(3):305-322. doi: 10.2174/1573396320666230801091558.
The immunology of Epstein-Barr virus-induced disease.
Taylor GS, Long HM, Brooks JM, Rickinson AB, Hislop AD.
Annu Rev Immunol. 2015;33:787-821. doi: 10.1146/annurev-immunol-032414-112326. Epub 2015 Feb 11.
Chronic active Epstein-Barr virus disease: molecular pathogenesis, evolving concepts, and emerging therapies.
Kimura H, Cohen JI.
Blood. 2026 Apr 2;147(14):1562-1573. doi: 10.1182/blood.2025032277.
Epstein-Barr virus and its association with disease - a review of relevance to general practice.
Fugl A, Andersen CL.
BMC Fam Pract. 2019 May 14;20(1):62. doi: 10.1186/s12875-019-0954-3.
Chronic, active Epstein-Barr virus infection.
Maia DM, Peace-Brewer AL.
Curr Opin Hematol. 2000 Jan;7(1):59-63. doi: 10.1097/00062752-200001000-00011.
[Chronic active Epstein-Barr virus infection].
Kimura H.
Uirusu. 2011 Dec;61(2):163-73. doi: 10.2222/jsv.61.163.
Haemophagocytic lymphohistiocytosis and Epstein-Barr virus: a complex relationship with diverse origins, expression and outcomes.
El-Mallawany NK, Curry CV, Allen CE.
Br J Haematol. 2022 Jan;196(1):31-44. doi: 10.1111/bjh.17638. Epub 2021 Jun 24.
Virus-triggered secondary hemophagocytic lymphohistiocytosis.
Imashuku S, Morimoto A, Ishii E.
Acta Paediatr. 2021 Oct;110(10):2729-2736. doi: 10.1111/apa.15973. Epub 2021 Jun 22.
